<DOC>
	<DOCNO>NCT01599702</DOCNO>
	<brief_summary>The study prospective , non-controlled , open-label multi-centre pilot safety study iron isomaltoside 1000 ( Monofer® ) administer subject anaemia Inflammatory Bowel Disease ( IBD ) . Based upon haemoglobin ( Hb ) level , subject divide two treatment group , A B . Depending body weight , subject Treatment Group A receive total dose 1,500 mg 2,000 mg IV iron isomaltoside 1000 single infusion , whereas subject Treatment Group B receive total dose 2,500 mg 3,000 mg IV iron isomaltoside 1000 divide two administration .</brief_summary>
	<brief_title>Iron Isomaltoside 1000 ( Monofer® ) Administered High Dosing Regimen Subjects With Inflammatory Bowel Disease</brief_title>
	<detailed_description>Subjects diagnosis IBD ( Crohn 's disease ulcerative colitis ) IDA ( Iron Deficiency Anaemia ) without concomi-tant inflammation enrol receive high dose IV iron isomaltoside 1000 .</detailed_description>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>1 . Subjects age ≥ 18 year 2 . Subjects diagnose IBD either remission active 3 . Hb &lt; 12 g/dL woman Hb &lt; 13 g/dL men 4 . Subjects CRP upper limit normality must ferritin 100 µg/L , whereas subject CRP equal upper limit normality must ferritin 30 µg/L 5 . Willingness participate signing inform consent 1 . Patient judge physician need surgery due Crohn´s disease ulcerative colitis within next 2 month 2 . Anaemia predominantly cause factor IDA 3 . Iron overload disturbance utilisation iron ( e.g . haemochromatosis haemosiderosis ) 4 . Known hypersensitivity excipients iron isomaltoside 1000 5 . History multiple allergy 6 . Decompensated liver cirrhosis and/or know chronic viral hepatitis ( defined Alanine Aminotransferase ( ALAT ) &gt; 3 time upper limit normal ) 7 . Acute and/or chronic infection 8 . Body weight &lt; 50 kg 9 . Rheumatoid arthritis symptom sign active joint inflammation 10 . Pregnancy nursing . In order avoid pregnancy , woman postmenopausal , surgically sterile , use one follow contraceptive whole study period 5 day study end ( i.e . 5 time plasma biological halflife investigational medicinal product ) : intrauterine device hormonal contraceptive ( contraceptive pill , implant , transdermal patch , hormonal vaginal device injection prolong release ) 11 . Blood transfusion within previous 12 week 12 . Subjects history asthma , allergic eczema , atopic allergy 13 . Planned elective surgery study 14 . Untreated Vitamin B12 folate deficiency , define value low reference range 15 . Participation clinical study within 3 month prior Screening 16 . IV iron treatment within 8 week prior Screening 17 . Oral iron treatment within 1 week prior Screening 18 . Erythropoiesis Stimulating Agent ( ESA ) treatment within 8 week prior Screening 19 . Any medical condition , opinion Investigator , may cause subject unsuitable completion study place subject potential risk study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>IBD</keyword>
	<keyword>IDA</keyword>
	<keyword>Subjects</keyword>
	<keyword>diagnosis</keyword>
</DOC>